Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trial.

ABSTRACT:

Background

Ivermectin, an effective treatment for scabies, is not licensed for children weighing <15 kg. Pharmacokinetic modelling has shown a 3 mg dose in young children (2-4 years, weighing 10-14 kg) achieves comparable drug exposure to a 200 μg/kg dose in children aged ≥5 years. This trial evaluated a 3 mg dose in young children.

Methods

Multicentre, phase 2 trial in five health centres in Lao PDR. Children aged 2-4 years, weighing 10-14 kg with scabies received 3 mg ivermectin and had two plasma concentrations determined (Clinicaltrials.gov ID NCT05500326). On day 14, clinical outcomes and adverse effects were assessed, and a second dose given to complete treatment. The primary outcome was the mean plasma ivermectin exposure (AUC_0-∞) after the first dose (comp

SUBMITTER: Gwee A 

PROVIDER: S-EPMC11301252 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature